Lindbrook Capital LLC Has $265,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Lindbrook Capital LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 37.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,269 shares of the biopharmaceutical company’s stock after buying an additional 883 shares during the quarter. Lindbrook Capital LLC’s holdings in Gilead Sciences were worth $265,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. abrdn plc lifted its position in shares of Gilead Sciences by 89.0% in the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after purchasing an additional 1,772,887 shares in the last quarter. J.W. Cole Advisors Inc. raised its position in Gilead Sciences by 6.7% during the fourth quarter. J.W. Cole Advisors Inc. now owns 41,882 shares of the biopharmaceutical company’s stock valued at $3,393,000 after acquiring an additional 2,638 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in Gilead Sciences during the fourth quarter valued at approximately $74,000. Greenleaf Trust raised its position in Gilead Sciences by 6.4% during the fourth quarter. Greenleaf Trust now owns 40,491 shares of the biopharmaceutical company’s stock valued at $3,280,000 after acquiring an additional 2,429 shares in the last quarter. Finally, Resonant Capital Advisors LLC bought a new position in Gilead Sciences during the fourth quarter valued at approximately $219,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the topic of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Friday. Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Barclays dropped their price target on shares of Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Finally, Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $84.71.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Stock Up 0.3 %

Shares of NASDAQ GILD opened at $66.95 on Tuesday. The stock has a market cap of $83.36 billion, a PE ratio of 14.88, a PEG ratio of 0.92 and a beta of 0.19. The business has a fifty day moving average of $71.81 and a two-hundred day moving average of $76.51. Gilead Sciences, Inc. has a 52-week low of $65.90 and a 52-week high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same period in the previous year, the business posted $1.67 earnings per share. The firm’s revenue was down 3.7% compared to the same quarter last year. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 6.55 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.60%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.